Transition state analogue inhibitors of N-ribosyltransferases: new drugs by targeting nucleoside processing enzymes.
The characterization of the transition state structure of a number of N-ribosyltransferases has enabled the design and synthesis of some extremely powerful inhibitors of these enzymes. We have three generations of inhibitors for some nucleoside processing enzymes which are therapeutic targets, and the potency of these compounds confers special advantages in their development as new drugs against cancer, autoimmune diseases, microbial infections and malaria.
Evans
Gary B
GB
Carbohydrate Chemistry, Industrial Research Ltd., Lower Hutt, New Zealand.
Furneaux
Richard H
RH
Kelly
Peter M
PM
Schramm
Vern L
VL
Tyler
Peter C
PC
D000818:Animals; D002417:Cattle; D004791:Enzyme Inhibitors / Q000737:chemistry*; D006801:Humans; D009699:N-Glycosyl Hydrolases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors* / Q000737:chemistry
D004791:Enzyme Inhibitors; D011683:Purine-Nucleoside Phosphorylase; C021784:5'-methylthioadenosine phosphorylase; D009699:N-Glycosyl Hydrolases; C019606:adenosylhomocysteine nucleosidase